Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
Planned sales, announced before they happen

2 trading plans running, 13 Form 144 notices for $7.4M

10-Q, 10-K and Form 144

What BCRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Jun 18, 2024 to Dec 31, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Jon Stonehouse
Member of the Board of Directors
Adopted 10b5-1 plan Mar 3, 2026 10-Q May 6, 2026
Ron Dullinger
Chief Commercial Officer
Adopted 10b5-1 plan Mar 2, 2026 10-Q May 6, 2026
A. Machelle Sanders
Member of the Board of Directors
Adopted 10b5-1 plan Aug 14, 2025 10-Q Nov 4, 2025
Nancy J. Hutson, Ph.D.
Director, Chair of the Board
Adopted 10b5-1 plan Jun 18, 2024 10-Q Aug 6, 2024
Helen M. Thackray, M.D.
Chief Research & Development Officer
Ended 10b5-1 plan Nov 8, 2023 10-K Feb 27, 2024
Alane P. Barnes
Chief Legal Officer and Secretary
Ended 10b5-1 plan Nov 7, 2023 10-K Feb 27, 2024
Anthony J. Doyle
Chief Financial Officer and Treasurer
Ended 10b5-1 plan Nov 7, 2023 10-K Feb 27, 2024
Charles K. Gayer
Chief Commercial Officer
Ended 10b5-1 plan Nov 7, 2023 10-K Feb 27, 2024
Jon P. Stonehouse
President and Chief Executive Officer
Ended 10b5-1 plan Nov 7, 2023 10-K Feb 27, 2024
Show the other 1 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
May 18, 2026 Amy McKee
Director
11,180 $100K
May 13, 2026 Barnes Alane P
Officer
62,500 $596K
Mar 20, 2026 HEGGIE THERESA
Director
49,933 $505K
Mar 16, 2026 Barnes Alane P
Officer
150,000 $1.4M
Mar 2, 2026 Stonehouse Jon P
Director
305,995 $2.6M
Dec 22, 2025 Barnes Alane P
Officer
21,773 $167K
Dec 15, 2025 Barnes Alane P
Officer
21,210 $162K
Dec 3, 2025 Barnes Alane P
Officer
19,770 $151K
Dec 2, 2025 Barnes Alane P
Officer
50,906 $367K
Dec 1, 2025 Barnes Alane P
Officer
91,004 $644K
Nov 25, 2025 Helen M Thackray
Officer
48,229 $328K
Nov 21, 2025 Helen Thackray
Officer
43,275 $308K
Nov 13, 2025 SANDERS MACHELLE
Officer
9,600 $69K
Show the other 5 notices

From the Form 144 XML filed with the SEC, since Nov 13, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.